NCT04751929View on ClinicalTrials.gov

Abemaciclib With or Without Atezolizumab for mCRPC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 20, 2021

Primary Completion Date

June 17, 2024

Study Completion Date

December 20, 2025

Conditions
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Interventions
DRUG

Abemaciclib

Taken orally 2x daily

DRUG

Atezolizumab

Intravenously Day 1 of 21 day cycle

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER